Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | TK2 | O00142 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL778861 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL542736 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL16189745 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12286396 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL2922181 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL7882259 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL3437225 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL23486 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL21078835 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL3437224 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106460040-A | Isothermal amplification under low salt conditions | 通用电气公司 | 2017-02-22 | — | — | CN | claimed |
| CN-103038361-B | Kits and Methods | 西森斯公司 | 2017-02-08 | — | — | CN | claimed |
| CN-103347888-B | Novel iridium-based complexes for ECL | 霍夫曼-拉罗奇有限公司 | 2016-12-21 | — | — | CN | claimed |
| CN-104093850-B | Methods and kits for reducing non-specific nucleic acid amplification | 通用电气公司 | 2016-12-07 | — | — | CN | claimed |
| CN-106074569-A | Momordica grosvenori alcohol application in preparation antiviral drugs | 成都普睿法药物研发有限公司 | 2016-11-09 | — | — | CN | claimed |
| CN-105968016-A | Carbonic ester type photosensitive reagent and preparation method thereof as well as preparation method of 5'-photolabile dN | 石平 | 2016-09-28 | — | — | CN | claimed |
| CN-103635576-B | Compositions and methods for inhibiting gene expression of hepatitis B virus | 箭头研究公司 | 2016-09-21 | — | — | CN | claimed |
| CN-105849251-A | Nucleoside supplementation for promoting cellular function, genetic stability and regenerative applications | 加利福尼亚大学董事会 | 2016-08-10 | — | — | CN | claimed |
| CN-105424821-A | Method for screening out components with genetic toxicity from natural products | SHANGHAI BAINIAN SHIDANDE INSPECTION TECH CO LTD | 2016-03-23 | — | — | CN | claimed |
| CN-105287617-A | Application of hypoxanthine, hypoxanthine riboside, xanthine, xanthosine or any combination thereof in preparation of medicines for treating tumors | CUI XIULING | 2016-02-03 | — | — | CN | claimed |
| CN-101835374-A | Substituted nucleoside derivatives with antiviral and antimicrobial properties | EASTERN VIRGINIA MED SCHOOL | 2010-09-15 | — | — | CN | claimed |
| CN-101094594-A | Modulation of immunostimulatory properties by small oligonucleotide-based compounds | HYBRIDON INC (US) | 2007-12-26 | — | — | CN | claimed |
| CN-101031308-A | Prodrugs activated by rna-dependent dna-polymerases | PROTERA S R L (IT) | 2007-09-05 | — | — | CN | claimed |
| CN-1309418-C | Immunostimulatory oligodeoxynucleotides | CISTEM BIOTECHNOLOGIES GMBH (AT) | 2007-04-11 | — | — | CN | claimed |
| CN-1925750-A | Modulation of LINE-1 reverse transcriptase | ALT SOLUTIONS INC (US) | 2007-03-07 | — | — | CN | claimed |
| CN-1921882-A | Allogeneic tumor therapeutic agent | MOLOGEN AG (DE) | 2007-02-28 | — | — | CN | claimed |
| CN-1049357-C | Treatment of human viral infection by dsRNA combined with viral inhibitors | HEM RES INC (US) | 2000-02-16 | — | — | CN | claimed |
| CN-1129573-A | Antiviral Drug Acyclovir Percutaneous Absorption Preparation | HU YOUPU (CN) | 1996-08-28 | — | — | CN | claimed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
| US-4783402-A | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1988-11-08 | — | — | US | claimed |